Effects of diltiazem-induced calcium blockade upon exercise capacity in effort angina due to chronic coronary artery disease

Reginald Low, Patricia Takeda, Garrett Lee, Dean T. Mason, Najam A. Awan, Anthony N. DeMaria

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Few data are available regarding the effects of calcium blockade upon exercise tolerance in patients with stable effort angina due to coronary artery disease (CAD). Therefore we compared the effects of the calcium blocking agent, diltiazem (D), to placebo (P) in 12 patients with chronic effort angina and catheterization documented fixed CAD. The 8-week total protocol consisted of a 1-week baseline period followed by the double-blind randomized crossover alternate 1-week administration of P and D in doses of 120, 180, and 240 mg. Maximal exercise tests (MET) were performed at the end of each 1-week period, while rest radionuclide ventriculography (RVG) was obtained during 240 mg D and corresponding crossover P. Resting heart rate decreased from baseline and initial P at D doses of 60 and 240 mg, but not from P during crossover period. No changes were observed at any dose of D either at rest or during MET in systolic blood pressure or rate · pressure double product. D at 240 mg, but not lower doses, increased MET duration (437 vs 490 seconds, p < 0.01) and time to angina (383 vs 441 seconds, p < 0.01). Ejection fraction by RVG was greater with D than P (0.54 vs 0.50, p < 0.05). Thus these data indicate that calcium blockade with diltiazem provides antianginal efficacy by reducing myocardial oxygen demand, and increases exercise tolerance without depression of myocardial performance in effort angina patients with fixed chronic CAD.

Original languageEnglish (US)
Pages (from-to)713-718
Number of pages6
JournalAmerican Heart Journal
Volume101
Issue number6
DOIs
StatePublished - 1981

Fingerprint

Diltiazem
Exercise Test
Radionuclide Ventriculography
Coronary Artery Disease
Exercise Tolerance
Exercise
Calcium
Blood Pressure
Stable Angina
Catheterization
Heart Rate
Placebos
Oxygen
Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of diltiazem-induced calcium blockade upon exercise capacity in effort angina due to chronic coronary artery disease. / Low, Reginald; Takeda, Patricia; Lee, Garrett; Mason, Dean T.; Awan, Najam A.; DeMaria, Anthony N.

In: American Heart Journal, Vol. 101, No. 6, 1981, p. 713-718.

Research output: Contribution to journalArticle

Low, Reginald ; Takeda, Patricia ; Lee, Garrett ; Mason, Dean T. ; Awan, Najam A. ; DeMaria, Anthony N. / Effects of diltiazem-induced calcium blockade upon exercise capacity in effort angina due to chronic coronary artery disease. In: American Heart Journal. 1981 ; Vol. 101, No. 6. pp. 713-718.
@article{a8ed57bcc6d94b3590c1d08909b6add8,
title = "Effects of diltiazem-induced calcium blockade upon exercise capacity in effort angina due to chronic coronary artery disease",
abstract = "Few data are available regarding the effects of calcium blockade upon exercise tolerance in patients with stable effort angina due to coronary artery disease (CAD). Therefore we compared the effects of the calcium blocking agent, diltiazem (D), to placebo (P) in 12 patients with chronic effort angina and catheterization documented fixed CAD. The 8-week total protocol consisted of a 1-week baseline period followed by the double-blind randomized crossover alternate 1-week administration of P and D in doses of 120, 180, and 240 mg. Maximal exercise tests (MET) were performed at the end of each 1-week period, while rest radionuclide ventriculography (RVG) was obtained during 240 mg D and corresponding crossover P. Resting heart rate decreased from baseline and initial P at D doses of 60 and 240 mg, but not from P during crossover period. No changes were observed at any dose of D either at rest or during MET in systolic blood pressure or rate · pressure double product. D at 240 mg, but not lower doses, increased MET duration (437 vs 490 seconds, p < 0.01) and time to angina (383 vs 441 seconds, p < 0.01). Ejection fraction by RVG was greater with D than P (0.54 vs 0.50, p < 0.05). Thus these data indicate that calcium blockade with diltiazem provides antianginal efficacy by reducing myocardial oxygen demand, and increases exercise tolerance without depression of myocardial performance in effort angina patients with fixed chronic CAD.",
author = "Reginald Low and Patricia Takeda and Garrett Lee and Mason, {Dean T.} and Awan, {Najam A.} and DeMaria, {Anthony N.}",
year = "1981",
doi = "10.1016/0002-8703(81)90605-0",
language = "English (US)",
volume = "101",
pages = "713--718",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Effects of diltiazem-induced calcium blockade upon exercise capacity in effort angina due to chronic coronary artery disease

AU - Low, Reginald

AU - Takeda, Patricia

AU - Lee, Garrett

AU - Mason, Dean T.

AU - Awan, Najam A.

AU - DeMaria, Anthony N.

PY - 1981

Y1 - 1981

N2 - Few data are available regarding the effects of calcium blockade upon exercise tolerance in patients with stable effort angina due to coronary artery disease (CAD). Therefore we compared the effects of the calcium blocking agent, diltiazem (D), to placebo (P) in 12 patients with chronic effort angina and catheterization documented fixed CAD. The 8-week total protocol consisted of a 1-week baseline period followed by the double-blind randomized crossover alternate 1-week administration of P and D in doses of 120, 180, and 240 mg. Maximal exercise tests (MET) were performed at the end of each 1-week period, while rest radionuclide ventriculography (RVG) was obtained during 240 mg D and corresponding crossover P. Resting heart rate decreased from baseline and initial P at D doses of 60 and 240 mg, but not from P during crossover period. No changes were observed at any dose of D either at rest or during MET in systolic blood pressure or rate · pressure double product. D at 240 mg, but not lower doses, increased MET duration (437 vs 490 seconds, p < 0.01) and time to angina (383 vs 441 seconds, p < 0.01). Ejection fraction by RVG was greater with D than P (0.54 vs 0.50, p < 0.05). Thus these data indicate that calcium blockade with diltiazem provides antianginal efficacy by reducing myocardial oxygen demand, and increases exercise tolerance without depression of myocardial performance in effort angina patients with fixed chronic CAD.

AB - Few data are available regarding the effects of calcium blockade upon exercise tolerance in patients with stable effort angina due to coronary artery disease (CAD). Therefore we compared the effects of the calcium blocking agent, diltiazem (D), to placebo (P) in 12 patients with chronic effort angina and catheterization documented fixed CAD. The 8-week total protocol consisted of a 1-week baseline period followed by the double-blind randomized crossover alternate 1-week administration of P and D in doses of 120, 180, and 240 mg. Maximal exercise tests (MET) were performed at the end of each 1-week period, while rest radionuclide ventriculography (RVG) was obtained during 240 mg D and corresponding crossover P. Resting heart rate decreased from baseline and initial P at D doses of 60 and 240 mg, but not from P during crossover period. No changes were observed at any dose of D either at rest or during MET in systolic blood pressure or rate · pressure double product. D at 240 mg, but not lower doses, increased MET duration (437 vs 490 seconds, p < 0.01) and time to angina (383 vs 441 seconds, p < 0.01). Ejection fraction by RVG was greater with D than P (0.54 vs 0.50, p < 0.05). Thus these data indicate that calcium blockade with diltiazem provides antianginal efficacy by reducing myocardial oxygen demand, and increases exercise tolerance without depression of myocardial performance in effort angina patients with fixed chronic CAD.

UR - http://www.scopus.com/inward/record.url?scp=0019428015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019428015&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(81)90605-0

DO - 10.1016/0002-8703(81)90605-0

M3 - Article

VL - 101

SP - 713

EP - 718

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6

ER -